# Trevi Therapeutics, Inc. (TRVI) Stock Analysis: A Biotech Gem with Over 100% Upside Potential

- Link: https://www.directorstalkinterviews.com/trevi-therapeutics-inc-trvi-stock-analysis-a-biotech-gem-with-over-100-upside-potential/4121245589
- Published: 2026-03-20T11:27:15+00:00
- Author: Madison Wilson

Investors with an eye on the healthcare sector, particularly in biotechnology, may
want to pay close attention to Trevi Therapeutics, Inc. (NASDAQ: TRVI). This promising
clinical-stage biopharmaceutical company, headquartered in New Haven, Connecticut,
is making notable strides in developing treatments for chronic cough conditions,
with its flagship product Haduvio currently undergoing clinical trials. With a market
cap of $1.37 billion and an average analyst target price suggesting a potential 
upside of 102.21%, Trevi Therapeutics is capturing the attention of investors seeking
high-growth opportunities.

Currently trading at $10.70, Trevi Therapeutics’ stock price sits within its 52-
week range of $5.28 to $14.17. Despite the recent price stability, indicated by 
a negligible price change of 0.01, the stock’s technical indicators reveal intriguing
insights. The RSI (Relative Strength Index) at 25.60 suggests the stock is in oversold
territory, which might indicate a potential reversal or buying opportunity for astute
investors. Furthermore, the stock’s 50-day moving average of $11.18 and 200-day 
moving average of $9.64 provide a glimpse into its recent momentum and long-term
growth trajectory.

However, investors should consider the challenges inherent in investing in a company
that has yet to achieve profitability. Trevi Therapeutics currently reports a negative
EPS of -0.37 and a concerning Return on Equity (ROE) of -30.23%. Additionally, the
free cash flow stands at -$27.86 million, underscoring the company’s need to secure
additional funding or achieve significant partnerships to sustain its operations
and continue its clinical trials.

On the valuation front, traditional metrics such as P/E and PEG ratios are not applicable,
given the company’s current financial posture. The forward P/E ratio of -18.21 indicates
that the market is pricing in future expectations rather than current earnings, 
a common scenario for biotech firms in the development stage. The absence of a dividend
yield further emphasizes Trevi’s focus on reinvesting in its growth and development
pipeline rather than distributing profits to shareholders.

Despite these challenges, analyst sentiment remains overwhelmingly positive, with
11 buy ratings and no hold or sell recommendations. The target price range of $16.00
to $27.00 suggests a robust belief in the company’s potential to capitalize on its
pipeline products, particularly Haduvio. The product’s ongoing clinical trials and
potential market applicability for chronic cough conditions could serve as significant
catalysts for stock appreciation if successful.

Trevi Therapeutics’ strategic license agreement with Keenova Therapeutics plc adds
another layer of potential, giving the company a competitive edge in developing 
and commercializing nalbuphine hydrochloride-based products. This collaboration 
may accelerate Trevi’s path to market, expanding its therapeutic offerings and enhancing
shareholder value.

For investors with a tolerance for risk and a long-term horizon, Trevi Therapeutics
presents a compelling opportunity. The combination of a promising drug pipeline,
positive analyst ratings, and significant potential upside makes TRVI a stock worth
considering in the high-stakes world of biotech investing. However, potential investors
should remain mindful of the inherent risks associated with clinical-stage companies
and the volatility that can accompany such investments.

Share on: